FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4324136461> ?p ?o ?g. }

• W4324136461 endingPage "65" @default.
• W4324136461 startingPage "65" @default.
• W4324136461 abstract "65 Background: CR is an important clinical indicator of disease progression and worsening overall survival among pts with mCSPC. This study describes real-world time-to-CR progression in an oncology setting among pts with mCSPC who initiated APA, ENZ, or ABI in the United States. Methods: Clinical data from the Flatiron Metastatic Prostate Cancer (PC) Core Registry Electronic DataMart (1/1/2013 – 07/31/2022) were evaluated. Metastatic pts without evidence of CR before initiating a next-generation androgen inhibitor (AAI) were classified into exclusive treatment cohorts based on the start date (index date) for APA, ENZ, or ABI. CR was identified by a Flatiron algorithm searching for: 1) mention of CR in patient charts, 2) rising prostate-specific antigen (PSA) levels documented from laboratory testing, or 3) mention of rising PSA while on hormonal therapy from unstructured data sources. Pts had ≥12 months (mo) of clinical data pre-index date and were followed from the index date until the end of clinical activity (including death) or data availability. The proportion of pts developing CR was described separately for each cohort using Kaplan-Meier analysis up to 24 mo post-index, with no adjustment for baseline confounders. CR progression rates in the current analysis were descriptively compared to those observed in Phase 3 trials where available. Results: A total of 155 APA, 385 ENZ and 711 ABI pts were evaluated. Mean age at index was ~73 years in each group. Mean follow-up was 12.8 mo (APA), 13.4 mo (ENZ) and 20.6 mo (ABI). Use of androgen deprivation therapy prior to initiation of AAI was observed in ~85% of pts. The median time between documented metastasis and the index date was 2.3 mo (APA), 2.8 mo (ENZ), and 2.3 mo (ABI). Progression rates to CR are shown. By 24 mo, the median time-to-CR was not reached with any treatment studied. By 24 mo, progression to CR was observed in 26% of APA pts in this analysis (32% in TITAN); 36% of ENZ pts in this analysis (25% in ARCHES); and 33% of ABI pts in this analysis (progression to CR not reported in LATITUDE). Conclusions: In this real-world database, the observed proportions of pts progressing to CRPC for the APA and ENZ cohorts were generally consistent with results of Phase 3 trials and include a small proportion of pts with early progression to CRPC. Increased physician awareness of the benefits of early initiation of an AAI along with identification of baseline biomarkers associated with early progression to CRPC may improve clinical outcomes. [Table: see text]" @default.
• W4324136461 created "2023-03-15" @default.
• W4324136461 creator A5004841700 @default.
• W4324136461 creator A5005489604 @default.
• W4324136461 creator A5013545031 @default.
• W4324136461 creator A5019269759 @default.
• W4324136461 creator A5027449699 @default.
• W4324136461 creator A5041982049 @default.
• W4324136461 creator A5080507578 @default.
• W4324136461 creator A5084091780 @default.
• W4324136461 creator A5090831117 @default.
• W4324136461 date "2023-02-20" @default.
• W4324136461 modified "2023-10-17" @default.
• W4324136461 title "Real-world time-to-castration resistance (CR) among patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) initiating apalutamide (APA), enzalutamide (ENZ), or abiraterone acetate (ABI) from an oncology database." @default.
• W4324136461 doi "https://doi.org/10.1200/jco.2023.41.6_suppl.65" @default.
• W4324136461 hasPublicationYear "2023" @default.
• W4324136461 type Work @default.
• W4324136461 citedByCount "0" @default.
• W4324136461 crossrefType "journal-article" @default.
• W4324136461 hasAuthorship W4324136461A5004841700 @default.
• W4324136461 hasAuthorship W4324136461A5005489604 @default.
• W4324136461 hasAuthorship W4324136461A5013545031 @default.
• W4324136461 hasAuthorship W4324136461A5019269759 @default.
• W4324136461 hasAuthorship W4324136461A5027449699 @default.
• W4324136461 hasAuthorship W4324136461A5041982049 @default.
• W4324136461 hasAuthorship W4324136461A5080507578 @default.
• W4324136461 hasAuthorship W4324136461A5084091780 @default.
• W4324136461 hasAuthorship W4324136461A5090831117 @default.
• W4324136461 hasConcept C121608353 @default.
• W4324136461 hasConcept C126322002 @default.
• W4324136461 hasConcept C143998085 @default.
• W4324136461 hasConcept C2775832370 @default.
• W4324136461 hasConcept C2776551883 @default.
• W4324136461 hasConcept C2777899217 @default.
• W4324136461 hasConcept C2780192828 @default.
• W4324136461 hasConcept C29456083 @default.
• W4324136461 hasConcept C41008148 @default.
• W4324136461 hasConcept C61367390 @default.
• W4324136461 hasConcept C71924100 @default.
• W4324136461 hasConcept C72563966 @default.
• W4324136461 hasConcept C77088390 @default.
• W4324136461 hasConceptScore W4324136461C121608353 @default.
• W4324136461 hasConceptScore W4324136461C126322002 @default.
• W4324136461 hasConceptScore W4324136461C143998085 @default.
• W4324136461 hasConceptScore W4324136461C2775832370 @default.
• W4324136461 hasConceptScore W4324136461C2776551883 @default.
• W4324136461 hasConceptScore W4324136461C2777899217 @default.
• W4324136461 hasConceptScore W4324136461C2780192828 @default.
• W4324136461 hasConceptScore W4324136461C29456083 @default.
• W4324136461 hasConceptScore W4324136461C41008148 @default.
• W4324136461 hasConceptScore W4324136461C61367390 @default.
• W4324136461 hasConceptScore W4324136461C71924100 @default.
• W4324136461 hasConceptScore W4324136461C72563966 @default.
• W4324136461 hasConceptScore W4324136461C77088390 @default.
• W4324136461 hasFunder F4320317188 @default.
• W4324136461 hasIssue "6_suppl" @default.
• W4324136461 hasLocation W43241364611 @default.
• W4324136461 hasOpenAccess W4324136461 @default.
• W4324136461 hasPrimaryLocation W43241364611 @default.
• W4324136461 hasRelatedWork W2263206436 @default.
• W4324136461 hasRelatedWork W2309274182 @default.
• W4324136461 hasRelatedWork W2768688864 @default.
• W4324136461 hasRelatedWork W2770702948 @default.
• W4324136461 hasRelatedWork W2776594178 @default.
• W4324136461 hasRelatedWork W3023947295 @default.
• W4324136461 hasRelatedWork W3197069188 @default.
• W4324136461 hasRelatedWork W4205706045 @default.
• W4324136461 hasRelatedWork W4226040508 @default.
• W4324136461 hasRelatedWork W4229076799 @default.
• W4324136461 hasVolume "41" @default.
• W4324136461 isParatext "false" @default.
• W4324136461 isRetracted "false" @default.
• W4324136461 workType "article" @default.